Literature DB >> 6299232

Characterization of an herpes simplex virus type 2 mutant, which is resistant to acycloguanosine and causes fusion of BSC1 cells.

E Katz, E Margalith.   

Abstract

A mutant of herpes simplex virus type 2, which induces low levels of thymidine-kinase activity in infected BSC1 cells and consequently able to grow in the presence of acycloguanosine, was isolated. This mutant has also been shown to cause fusion of BSC1 cells. In BSC1 cells, co-infected with the wild-type strain and the mutant, the yield of each of the two viruses was normal but the rounding and aggregation of cells observed, resembled that found in wild-type infected cultures. When the mixed infection was performed in the presence of acycloguanosine (100 micrometers), the growth of the two virus strains was inhibited, as well as the cytopathic effect in the cultures. It is suggested that under these conditions, the thymidine-kinase which was induced in the infected cells by the wild-type strain, phosphorylated acycloguanosine and the activated drug formed, inhibited the growth of the two viruses by interference in their DNA syntheses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6299232     DOI: 10.1007/bf01314705

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  33 in total

1.  Phosphonoacetic acid-resistant herpes simplex virus infection in hairless mice.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

2.  Identification of the herpes simplex virus DNA polymerase gene.

Authors:  D J Purifoy; R B Lewis; K L Powell
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

3.  The expression of the syn- gene of herpes simplex virus type 1. II. Requirements for macromolecular synthesis.

Authors:  J M Keller
Journal:  Virology       Date:  1976-07-15       Impact factor: 3.616

4.  Effect of 2-deoxy-D-glucose on cell fusion induced by Newcastle disease and herpes simplex viruses.

Authors:  W R Gallaher; D B Levitan; H A Blough
Journal:  Virology       Date:  1973-09       Impact factor: 3.616

5.  Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity.

Authors:  A T Jamieson; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1974-09       Impact factor: 3.891

6.  Dependence of herpes simplex virus type 1-induced cell fusion on cell type.

Authors:  D J Bzik; S Person
Journal:  Virology       Date:  1981-04-15       Impact factor: 3.616

7.  Genetic studies of cell fusion induced by herpes simplex virus type 1.

Authors:  G S Read; S Person; P M Keller
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

8.  In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).

Authors:  K O Smith; W L Kennell; R H Poirier; F T Lynd
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.

Authors:  H J Field; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

10.  Herpes simplex virus resistance and sensitivity to phosphonoacetic acid.

Authors:  R W Honess; D H Watson
Journal:  J Virol       Date:  1977-02       Impact factor: 5.103

View more
  3 in total

1.  Antiviral activity of SK&F 21681 against herpes simplex virus.

Authors:  E Katz; E Margalith
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

2.  Sensitivity in vitro of herpes simplex virus isolates to human fibroblast interferon.

Authors:  S Leventon-Kriss; M Movshovitz; Z Smetana; M Shewach-Millet; T Doerner; T Gotlieb-Stematsky
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

3.  An acyclovir-resistant strain of herpes simplex virus type 2 which is highly virulent for mice.

Authors:  S Sakuma; M Yamamoto; Y Kumano; R Mori
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.